Lund University
http://www.lu.se/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lund University
Novo Nordisk Teams With Aspect Biosystems On Diabetes Cell Therapy
Aspect says its bioprinted tissue therapeutics include immune-resistant encapsulation, which Novo Nordisk hopes will offer a safer approach to type 1 diabetes cell therapy.
Asia Deal Watch: China Grand, ETheRNA Create mRNA Vaccine JV
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Finance Watch: Gossamer Works Around The Shutdown To Price Its $230m IPO
Gossamer took an infrequently used path to go public during a US government shutdown that's kept the SEC from processing new offerings. Also, IPO filings (and withdrawals) and follow-on offerings continued during the shutdown, while VC deals keep up a brisk pace.
Deal Watch: Novo’s Increased Cell Therapy Commitment Includes Stem Cell Pact With BioLamina
Also, TapImmune merger with Marker could yield T-cell therapies that address multiple tumor-associated antigens with a better safety profile than CAR-T therapy. Bluebird and Medigene expand their TCR therapy collaboration.
Company Information
- Industry
- Academic and Research Institutions
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice